Unrelated cord blood transplantation for an infant with chemotherapy-resistant progressive Langerhans cell histiocytosis

Journal of Pediatric Hematology/oncology
A SuminoeT Hara

Abstract

The authors describe a patient successfully treated with unrelated cord blood transplantation (CBT) for chemotherapy-resistant progressive Langerhans cell histiocytosis (LCH). An 8-month-old boy had LCH diagnosed based on the histologic examination of skin lesions. Despite intensive chemotherapy and immunotherapy, the disease was progressive, with organ dysfunction. He received unrelated CBT after a conditioning regimen consisting of total body irradiation, etoposide, and melphalan. He was in complete remission 12 months after the transplantation. The authors suggest that CBT could be considered in the treatment of patients with chemotherapy-resistant progressive LCH, especially if there are no available human leukocyte antigen-matched family donors.

References

Jan 1, 1986·Medical and Pediatric Oncology·P Grundy, R Ellis
Sep 1, 1981·Medicine·J S GreenbergerJ R Cassady
Jan 1, 1994·Medical and Pediatric Oncology·H GadnerS Ladisch
May 1, 1996·Medical and Pediatric Oncology·R Rivera-LunaG Martínez-Guerra
Apr 30, 1998·Hematology/oncology Clinics of North America·R J ArceciJ Pritchard
Nov 26, 1998·The New England Journal of Medicine·P RubinsteinC E Stevens
Oct 3, 1999·Pediatric Hematology and Oncology·J BraierJ Goldberg

❮ Previous
Next ❯

Citations

Sep 3, 2004·Journal of Pediatric Hematology/oncology·Tadashi MatsubayashiRie Matsubayashi
Apr 29, 2014·The Journal of Surgical Research·Samuel GolpanianSeth R Thaller
May 3, 2006·Pediatric Hematology and Oncology·Judit MüllerUNKNOWN Hungarian Pediatric Oncology Network
Apr 12, 2003·Leukemia & Lymphoma·Keiichi IsoyamaUNKNOWN Japanese Cord Blood Bank Network

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Journal of Cranio-maxillo-facial Surgery : Official Publication of the European Association for Cranio-Maxillo-Facial Surgery
Arnd BartnickRainer Schmelzle
© 2022 Meta ULC. All rights reserved